Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veracyte Inc VCYT

Healthcare Biotechnology
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory... see more

Recent & Breaking News (NDAQ:VCYT)

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

Business Wire 13 days ago

New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Business Wire April 22, 2024

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

Business Wire April 16, 2024

Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

Business Wire February 27, 2024

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Business Wire February 22, 2024

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

Business Wire February 21, 2024

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Business Wire February 8, 2024

Veracyte Completes Acquisition of C2i Genomics

Business Wire February 6, 2024

Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform

Business Wire January 8, 2024

Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire December 12, 2023

Real-World Data Presented at SUO 2023 Show that Veracyte's Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

Business Wire December 1, 2023

Clinical Validation Data Published in CHEST Demonstrate that Veracyte's Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

Business Wire November 29, 2023

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

Business Wire November 22, 2023

Veracyte Announces Third Quarter 2023 Financial Results

Business Wire November 7, 2023

Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally

Business Wire November 7, 2023

Veracyte to Participate in the Stephens Annual Investment Conference

Business Wire November 2, 2023

Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development

Business Wire October 27, 2023

Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023

Business Wire October 17, 2023

New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte's Envisia Genomic Classifier for Patients with Interstitial Lung Disease

Business Wire October 12, 2023

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte's Decipher Prostate Genomic Classifier

Business Wire October 4, 2023